STAT June 21, 2024
Buenos dias! Writing from one of the more unique locations in my tenure as a Readout author…. Hola from a mercado in Mexico City. On tap today: Early studies show that checkpoint inhibitors may be more effective if combined with JAK inhibitors. Also, more promising anti-obesity results and perhaps a more potent PrEP for HIV.
Sarepta gene therapy approved for most Duchenne patients
The FDA yesterday dramatically expanded its approval for Elevidys, a gene therapy for Duchenne muscular dystrophy, authorizing access for nearly all patients with the fatal muscle-wasting disease.
It’s clear that the treatment, made by Sarepta Therapeutics, won’t be a panacea — “No one pretends this is a cure,” one patient’s mother told STAT’s Jason Mast — but...